Use of any vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment.
Within 21 days of treatment initiation:\r\nPlatelets >= 100,000/mcL
The patients' last dose of chemotherapy must be at least 3 weeks prior to initiation of study therapy
Severe infection within 4 weeks prior to initiation of study treatment;
Severe infection within 4 weeks before initiation of study treatment
Within 14 days of treatment initiation:\r\nPlatelets >= 100,000/mcL
Treatment with investigational therapy within 30 days prior to initiation of study treatment
Patients who have had chemotherapy (e.g., purine analogues, alkylating agents), radiation therapy, or participation in any investigational drug treatment within 4 weeks of initiation of DMF or at any time during the study
No prior lapatinib within 7 days prior to initiation of protocol treatment
Treatment with investigational therapy within 14 days prior to initiation of study treatment
Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
Had immunotherapy, radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment with an investigational product within 4 weeks prior to treatment initiation (or oral therapy within 1 week prior to treatment initiation).
Non-escalating steroid requirement at the time of consent and study drug initiation for the treatment of CNS symptoms
Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment
Severe infection within 4 weeks prior to initiation of study treatment
Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
Participant is able to complete a minimum of 14 days of study agent dosing prior to initiation of definitive treatment for their cancer
Use of any vaccines against infectious diseases within 4 weeks of initiation of study treatment.
Investigational therapy within 28 days prior to initiation of study treatment
Between days 28 and 50 post transplantation at the time of initiation of the study drug
Patients must be off all disease modifying therapy for MDS for 28 days prior to initiation of study treatment; patients may receive hydrocortisone prophylactically to prevent transfusion reactions
Performed within 10 business days of treatment initiation with the exception of beta- HCG (72 hours), if applicable: Platelets >= 75,000 / uL.
Patients who are receiving any other investigational agents. A minimum washout period of 28 days is required prior to the initiation of on study treatment.
Patients with microscopic hematuria (defined as > 100 red blood cells [RBCs] on urinalysis) or worsening urinary symptoms within 7 days prior to the initiation of study treatment.
Any prior PSA, MUC1, and/or brachyury-targeted immunotherapy (e.g., vaccine) must have been discontinued at least 12 weeks before initiation of study treatment; subjects must have recovered from all acute toxicities from prior treatment prior to screening for this study
Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to initiation of therapy. The use of live vaccines within 30 days before initiation of therapy. IMiDs, PIs and or corticosteroids within 2 weeks prior to initiation of therapy. Other investigational therapies and monoclonal antibodies (mAb) within 4 weeks of initiation of therapy Prednisone up to but no more than 10 mg orally once daily (q.d.) or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least 7 days prior to initiation of therapy
Treatment with any of the drugs listed in Section 8.4.5 at the time of study treatment initiation.
Severe infection within 4 weeks prior to initiation of study treatment
Indication for initiation of therapy
Herbal preparations are not allowed throughout the study, and should be discontinued 14 days prior to initiation of study treatment
Patients may not be taking any corticosteroid for any reason while on study and all corticosteroids must be stopped two weeks prior to initiation of study drug
Previous anticancer treatment must be discontinued at least 3 weeks prior to the initiation of study treatment (6 weeks for mitomycin C; 6 weeks for anti-androgen therapy if discontinued prior to treatment initiation, except 8 weeks for bicalutamide);
Have received any unapproved agent or device within 30 days before initiation of study treatment.
All patients must discontinue anti-platelet agents or anticoagulants 7 days prior to initiation of study drug
Have received treatment with any form of therapy with CYP17 inhibitory activity such as ketoconazole, aminoglutethimide, or an antiandrogen such as bicalutamide within 6 months of study treatment initiation
Current or previous treatment with investigational therapy in another therapeutic clinical trial interrupted less than 4 weeks before study treatment initiation.
Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within 4 weeks of initiation of study treatment.
Patient received investigational treatment within 2 weeks or immunotherapy or antibody therapy within 28 days prior to initiation of treatment with Toca 511, and/or has not recovered from toxicities associated with such treatment.
Surgery prior to enrollment within 28 days prior to the initiation of study treatment or unhealed surgical incision;
Prior courses of TSEBT (Note: localized skin-directed radiotherapy is allowed if administered at least 4 weeks prior to initiation on study).
Prior chemotherapy treatment for AML within 21 days from the initiation of HCT conditioning; Note, use of hydroxyurea or other low intensity treatment not intended to induce remission are acceptable
Participants in the study must permit targeted prostate biopsy prior to initiation of study treatment and at the time of fiducial marker placement
Patients must have stable topical medication regimen for 2 weeks prior to study initiation
History of treatment with canakinumab within the 12 months prior to study initiation
History of phototherapy within 2 weeks prior to study initiation
Radiotherapy within 21 days prior to initiation of study treatment
Loco-regional treatment within 4 weeks prior to initiation of study treatment.
The patient has not received stereotactic radiotherapy within 7 days prior to initiation of study treatment or whole-brain radiotherapy within 14 days prior to initiation of study treatment.
Any anti-lymphoma treatment within 6 months of treatment initiation.
Last chemotherapy at least 3 weeks from initiation of study treatment
Have received any unapproved agent or device within 30 days before initiation of study treatment.
Received the following within 7 days prior to the initiation of study treatment:
Treatment with investigational therapy within 14 days prior to initiation of study drug
Investigational therapy within 28 days prior to initiation of study treatment
Prior recent systemic or investigational therapy within 21 days of initiation of study treatment; an exception is that EGFR inhibitor may be continued up until 3 days of initiation of study treatment
Systemic strontium-89, samarium-153, rhenium-186, or rhenium-188 for bone metastases within 24 weeks prior to initiation of study treatment
Subjects who have completed sipuleucel-T (Provenge ®) treatment within 28 days of study drug initiation.
Radiotherapy within the 2 weeks before initiation of treatment. Palliative radiation treatment to nonindex or bone lesions performed less than 2 weeks before treatment initiation may be considered with medical monitor approval
Participant treated with any prior systemic therapy with the exception of the following:\r\n* Treatment by localized radiotherapy for a specific indication within 2 weeks of initiation of treatment\r\n* Treatment with corticosteroids, not to exceed the equivalent of 160 mg of dexamethasone over a four-week period before initiation of protocol therapy
Patients who have received chemotherapy within 3 weeks prior to the initiation of study treatment, or endocrine therapy within 2 weeks prior to the initiation of study treatment; if patients are already on trastuzumab, this medication may be continued
Patients who have participated in a prior investigational study within 3 weeks prior to initiation of study treatment
Severe infection within 4 weeks prior to initiation of study treatment
Treatment with chemotherapy (other than high-dose chemotherapy as described above) or differentiation therapy (such as retinoic acid) or immunotherapy (such as anti-GD2 antibody treatment) within 3 weeks prior to initiation of study drug or, if treatment included nitrosoureas, within 6 weeks prior to initiation of study drug
Treatment with thoracic or mediastinal radiotherapy within 3 weeks prior to initiation of study drug
Treatment with investigational therapy (with the exception of cancer therapies as described above) within 4 weeks prior to initiation of study drug
Treatment with herbal cancer therapy within 1 week prior to initiation of study drug
Serum bilirubin 1.5 x ULN, obtained within 14 days prior to initiation of study treatment
Serum creatinine =< 1.5 x ULN, obtained within 14 days prior to initiation of study treatment
Treatment for the studied cancer within 28 days prior to initiation of study treatment
Treatment with investigational therapy within 28 days prior to initiation of study treatment
Use of any vaccines against infectious diseases (e.g., influenza, varicella, etc.) within 4 weeks (28 days) of initiation of study therapy and 60 days after the last administration of the study medication.
Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment
Any investigation agents must be discontinued at least 30 days prior to study treatment initiation
The baseline brain MRI/CT must be performed less than 15 days prior to initiation of study treatment; otherwise it must be repeated
A brain MRI/CT must be performed less than 15 days prior to initiation of study treatment; otherwise it must be repeated
Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment
Subjects must be off any steroids 7 days prior to the initiation of treatment
Subjects must be off any curcumin, tumeric, or vitamin D supplements for 14 days prior to the initiation of treatment
Positive culture for or other clinical evidence of infection with bacteria or fungus within 14 days of the initiation of study treatment
Subjects must not have received other antineoplastic agents with therapeutic intent, excluding hydroxyurea and antimetabolites administered as part of maintenance chemotherapy, within 7 days prior to study treatment initiation
Patients who have received chemotherapy or radiotherapy within 4 weeks prior to enrollment are NOT eligible for participation \r\n* The exception to this is patients who are refractory to conventional initial induction chemotherapy (=< 2 courses) or to radiation; patients must have morphologic proof (from bone marrow aspirate, smears, or touch preps of marrow biopsy) of AML with > 10% blasts within 2 weeks prior to initiation of study therapy\r\n* The last dose of cytotoxic therapy (NOT including Hydrea, which is allowed) must have been given >= 14 days prior to initiation of study therapy\r\n* The last dose of biologic therapy must have been given >= 7 days prior to initiation of study therapy\r\n* The last dose of any investigational agent must have been given >= 14 days prior to initiation of study therapy
Prior therapy with strontium-89, samarium, rhenium-186 etidronate, chemotherapy or androgen biosynthesis inhibitors for prostate cancer is not allowed. Previous immunologic, homeopathic, natural, or alternative medicine therapies are acceptable provided treatment ended greater than 28 days prior to initiation of study drug
Within 8 weeks of treatment initiation (day 0), have received treatment with:\r\n* Imiquimod\r\n* Total body electron beam radiation\r\n* Investigational drugs or treatments
Subjects must be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroids for ?10 days prior to initiation of study treatment
Received >24 hours of systemic antibacterial therapy within 72 hours of initiation of inpatient IV study drug
Receiving any other therapies for cancer treatment (with the exception of gonadotropin-releasing hormone [GnRH] agonists for prostate cancer); Note: hydroxyurea is allowed before initiation of study treatment and for the first 5 days of study treatment
History of receiving any investigational treatment within 28 days of study medication initiation
Initiation of anti-tumor therapy including chemotherapy or investigational drug treatment within 30 days before beginning study
Patients must not have the following foods/ supplements at least 7 days prior to initiation of and during study treatment:
Initiation of a new drug therapy within the past 30 days prior to study commencement
Has, at the planned initiation of study drug, an uncontrolled infection.
All pre-treatment laboratory tests and scans must be performed within 14 days prior to initiation of treatment
Treatment with any anti-cancer therapy within 3 weeks prior to initiation of study treatment
Treatment with any anti-cancer therapy within 3 weeks prior to initiation of study treatment
Planned initiation, termination, or dose alteration of hydroxyurea during the study
Bilirubin =< 1.5 x ULN, within 14 days prior to initiation of study drug
Treatment with approved or investigational cancer therapy within 14 days prior to treatment initiation
Completed active treatment (surgery, chemotherapy, and/or radiotherapy) at least one month prior to study initiation (patients on continued hormone treatment will not be excluded)
Concomitant medication as follows:\r\n* Subjects treated with gabapentin or other anticonvulsant for neuropathic pain will be required to taper the medication and discontinue for at least 2 weeks prior to study initiation\r\n* Patients on antidepressant treatment for pain or depression (tricyclic antidepressants [TCAs], selective serotonin reuptake inhibitor [SSRI], serotonin–norepinephrine reuptake inhibitors [SNRIs] etc.) will be allowed to continue their medications provided they have been on a stable dose for at least 4 weeks before study initiation; no dose regimen changes of antidepressants will be allowed during the study period\r\n* Patients on around-the clock opioid treatment (including tramadol) will be allowed to continue their medication provided they have been on a stable dose for at least 4 weeks before study initiation; the maximum allowed dose of opioid will be equivalent to 60 mg oral morphine sulfate; patients with higher doses will be required to taper down their opioid dose to maximum 60mg oral morphine equivalent, and continue on stable dose for 4 weeks before enrollment in the study; pro re nata (PRN) short-acting opioids for painful CIPN treatment will not be allowed; patients receiving PRN short-acting opioids (with or without acetaminophen) for pain other than CIPN will be allowed up to 4 daily doses, with daily recording of analgesic consumption\r\n* Treatment with nonsteroidal anti-inflammatory drug (NSAIDs) will be discontinued at least 2 weeks before study initiation; however, low-dose aspirin (=< 325 mg/day) will be allowed
Patient participants must be at a point of treatment initiation/change or evaluation for treatment initiation/change
Within the first 3 weeks of initiation of a new type of therapy
Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within 4 weeks of initiation of study treatment.
Initiation of investigational agent =< 3 days after initiation of radiotherapy
Initiation of hormone therapy < 4 weeks prior to enrollment in the study
Use of any systemic antifungal therapy for > 72 hours during the week prior to study drug initiation
Willing to repeat RPFNA at 12 months following initiation of study agent
All visible papillary lesions must be macroscopically resected within 60 days of treatment initiation
Has vomited in the 24 hours prior to chemotherapy initiation on Treatment Day 1
Had at least 14 days for prior treatment to clear the body before initiation of DS-3201b administration (except for hydroxyurea that needs only 2 days for clearance)
Discontinuation of all other therapies (including radiotherapy or chemotherapy) for the treatment of iNHL >= 3 weeks before initiation of study treatment
Have discontinued all disease-modifying therapy for the primary cancer >28 days prior to initiation of study treatment. In addition, clinically significant toxicities associated with any prior therapy for the primary cancer, including investigational treatments, have resolved or stabilized to Grade ?1 toxicity >28 days prior to initiation of study treatment with the exception of neuropathy, which must have resolved to Grade ?2. Continuation of a stable dose (minimum of 28 days prior to study entry) of denosumab or bisphosphonate is permitted on study.
Have discontinued all disease-modifying therapy for the primary cancer for 28 days prior to initiation of study treatment.
Baseline (prior to the initiation of new ET), and;
Subsequently at 1, 2, 3 and 12 months after the initiation of therapy, and/or;
Pregnant or actively breastfeeding without intention to discontinue prior to initiation of study
